{"id":"apdc-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Chemotherapy-related myelosuppression"},{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL297150","moleculeType":"Small molecule","molecularWeight":"189.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"APDC (likely an immunomodulatory or checkpoint-related compound) is administered alongside standard chemotherapy regimens to potentiate both direct cytotoxic killing and immune-mediated tumor destruction. The combination approach aims to overcome chemotherapy resistance and improve overall survival by engaging both innate and adaptive immune mechanisms while maintaining chemotherapy efficacy.","oneSentence":"APDC is an immunotherapeutic agent combined with chemotherapy to enhance anti-tumor immune responses and cytotoxic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:02.578Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT02503150","phase":"PHASE3","title":"Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2015-07","conditions":"Metastatic Colorectal Cancer","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"APDC + Chemotherapy","genericName":"APDC + Chemotherapy","companyName":"Second Military Medical University","companyId":"second-military-medical-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"APDC is an immunotherapeutic agent combined with chemotherapy to enhance anti-tumor immune responses and cytotoxic effects. Used for Advanced or metastatic solid tumors (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}